Omeros Corporation, a biopharmaceutical company headquartered in the United States, is renowned for its innovative approach to drug development. Founded in 1994, Omeros has made significant strides in the fields of ophthalmology, immunology, and neurology, focusing on the discovery and commercialisation of novel therapeutics. The company’s flagship products, including the FDA-approved Omidria, exemplify its commitment to addressing unmet medical needs with unique formulations that enhance surgical outcomes. Omeros has established a strong market position, bolstered by its proprietary platform technologies and a robust pipeline of drug candidates. With a dedication to advancing patient care, Omeros continues to be a leader in the biopharmaceutical industry, driving forward with a vision of transformative therapies.
How does Omeros Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Omeros Corporation's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Omeros Corporation, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Omeros Corporation may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, Omeros Corporation's future climate commitments will be crucial for aligning with global standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Omeros Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

